Johnson & Johnson, a US-based healthcare and pharmaceuticals company, announced on Wednesday that it will hold a Business Review for the investment community on Thursday, 18 November 2021.

Company leaders will share a detailed review of its pharmaceuticals business, differentiated strategy and robust pipeline, and long-term growth outlook.

The Business Review will include: Comprehensive Pipeline Overviews for the company's Six Therapeutic Areas and Data Sciences available on a virtual platform beginning at 09:00 ET on 17 November 2021; A Live General Session on 18 November 2021 beginning at 08:30 ET and ending at approximately 13:00 ET, featuring: Enterprise remarks from current CEO and chairman, Alex Gorsky, incoming CEO Joaquin Duato and CFO Joe Wolk; Insights into Janssen's transformational innovation engine and commercial capabilities fuelling both short and long-term growth delivered by Jennifer Taubert, executive vice president, worldwide chairman and Mathai Mammen, Global Head, Janssen Research & Development; Spotlight presentations highlighting key product opportunities across the company's current and future pipeline; and Q&A sessions with leaders from the company's Executive Committee, and Janssen Research & Development, Commercial, and Supply Chain organisations

Those planning to attend the event can register at www.investor.jnj.com starting 1 November 2021. A replay and supporting content will be posted by the end of the day on 18 November 2021.